Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global Dual Specificity Mitogen Activated Protein Kinase Kinase 2 market in this environment.
In terms of revenue, this research report indicated that the global Dual Specificity Mitogen Activated Protein Kinase Kinase 2 market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Dual Specificity Mitogen Activated Protein Kinase Kinase 2 industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Array BioPharma Inc. aims at producing XX K Units Dual Specificity Mitogen Activated Protein Kinase Kinase 2 in 2020, with XX % production to take place in global market, AstraZeneca Plc accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Market
Array BioPharma Inc.
AstraZeneca Plc
Confluence Life Sciences, Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Merck & Co., Inc.
Merck KGaA
Novartis AG
...
Major Type of Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Covered in Prudent Markets report:
CIP-137401
CDD-450
MK-2206
Selumetinib Sulfate
Others
Application Segments Covered in Prudent Markets Market
Hospital
Clinic
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 CIP-137401 -Product Introduction and Major Manufacturers
1.1.2 CDD-450 -Product Introduction and Major Manufacturers
1.1.3 MK-2206 -Product Introduction and Major Manufacturers
1.1.4 Selumetinib Sulfate -Product Introduction and Major Manufacturers
1.1.5 Others -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027)
2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027)
3 Regional Market Analysis
3.1 China Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Market
3.1.1 Top Companies leading Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Development in China (2016-2021)
3.1.2 Sales Value of Major Company in China Market (2016-2021)
3.1.3 China Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2026-2027)
3.2 EU Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Market
3.2.1 Top Companies leading Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Development in EU (2016-2021)
3.2.2 Sales Value of Major Company in EU Market (2016-2021)
3.2.3 EU Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2026-2027)
3.3 USA Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Market
3.3.1 Top Companies leading Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Development in USA (2016-2021)
3.3.2 Sales Value of Major Company in USA Market (2016-2021)
3.3.3 USA Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2026-2027)
3.4 Japan Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Market
3.4.1 Top Companies leading Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Development in Japan (2016-2021)
3.4.2 Sales Value of Major Company in Japan Market (2016-2021)
3.4.3 Japan Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2026-2027)
3.5 India Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Market
3.5.1 Top Companies leading Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Development in India (2016-2021)
3.5.2 Sales Value of Major Company in India Market (2016-2021)
3.5.3 India Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2026-2027)
3.6 Southeast Asia Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Market
3.6.1 Top Companies leading Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Development in Southeast Asia (2016-2021)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021)
3.6.3 Southeast Asia Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2026-2027)
3.7 South America Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Market
3.7.1 Top Companies leading Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Development in South America (2016-2021)
3.7.2 Sales Value of Major Company in South America Market (2016-2021)
3.7.3 South America Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2026-2027)
4 Value Chain (Impact of COVID-19)
4.1 Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2027)
5.1 Global Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Sales and Growth Rate (2021-2027)
5.2 Global Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Sales Value and Growth Rate (2021-2027)
6 Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Competitive Analysis
6.1 Array BioPharma Inc.
6.1.1 Array BioPharma Inc. Company Profiles
6.1.2 Array BioPharma Inc. Product Introduction
6.1.3 Array BioPharma Inc. Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Production, Revenue (2016-2021)
6.1.4 SWOT Analysis
6.2 AstraZeneca Plc
6.2.1 AstraZeneca Plc Company Profiles
6.2.2 AstraZeneca Plc Product Introduction
6.2.3 AstraZeneca Plc Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Production, Revenue (2016-2021)
6.2.4 SWOT Analysis
6.3 Confluence Life Sciences, Inc.
6.3.1 Confluence Life Sciences, Inc. Company Profiles
6.3.2 Confluence Life Sciences, Inc. Product Introduction
6.3.3 Confluence Life Sciences, Inc. Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Production, Revenue (2016-2021)
6.3.4 SWOT Analysis
6.4 F. Hoffmann-La Roche Ltd.
6.4.1 F. Hoffmann-La Roche Ltd. Company Profiles
6.4.2 F. Hoffmann-La Roche Ltd. Product Introduction
6.4.3 F. Hoffmann-La Roche Ltd. Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Production, Revenue (2016-2021)
6.4.4 SWOT Analysis
6.5 GlaxoSmithKline Plc
6.5.1 GlaxoSmithKline Plc Company Profiles
6.5.2 GlaxoSmithKline Plc Product Introduction
6.5.3 GlaxoSmithKline Plc Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Production, Revenue (2016-2021)
6.5.4 SWOT Analysis
6.6 Merck & Co., Inc.
6.6.1 Merck & Co., Inc. Company Profiles
6.6.2 Merck & Co., Inc. Product Introduction
6.6.3 Merck & Co., Inc. Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Production, Revenue (2016-2021)
6.6.4 SWOT Analysis
6.7 Merck KGaA
6.7.1 Merck KGaA Company Profiles
6.7.2 Merck KGaA Product Introduction
6.7.3 Merck KGaA Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Production, Revenue (2016-2021)
6.7.4 SWOT Analysis
6.8 Novartis AG
6.8.1 Novartis AG Company Profiles
6.8.2 Novartis AG Product Introduction
6.8.3 Novartis AG Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Production, Revenue (2016-2021)
6.8.4 SWOT Analysis
7 Conclusion